Neurogene shareholders approve equity plan amendments, elect directors

Neurogene Inc.

Amendments to 2023 Equity Incentive Plan and ESPP approved; shares from prefunded warrants and convertible preferred counted in automatic share reserve increase.
Elected Sarah B. Noonberg and Robert 'Keith' Woods as Class II directors until 2028; each received >10.3M votes for.
Say-on-pay advisory vote passed with 7.72M for (68.7% of votes cast excluding broker non-votes).
Ratified Deloitte & Touche as independent auditor for FY2025; 99.9% of votes cast in favor.
Quorum of 11.48M shares (80.5% of voting power) present at the June 12, 2025 annual meeting.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.